Belimumab is linked to a reduced risk for all-cause mortality compared with azathioprine, methotrexate, and mycophenolate among patients with nonrenal SLE.

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...

-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...

Socioeconomic, regional, and racial disparities are among the relevant factors behind CKD mortality in SLE. Chronic kidney disease (CKD) remains a major cause of death among US patients with systemic ...

Mucormycosis is a life-threatening angioinvasive fungal infection caused by the Mucorales acidophilic fungi. In the article we report a case of cutaneous mucosporidiosis caused by infection with ...

ZÜRICH, CH / ACCESS Newswire / August 26, 2025 / Santersus AG today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its NucleoCapture(tm) ...

The European Alliance of Associations for Rheumatology has published new recommendations on core datasets to be used in systemic lupus erythematosus (SLE). The work defines a set of essential items ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Maureen A. McMahon ...

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop it in its tracks. By Nina Agrawal Jennifer Le’s doctor ticked through a ...

An oral therapy targeting toll-like receptors (TLR) 7 and 8 reduced disease activity in patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) with active lupus rash.

Merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demonstrating clinically meaningful reduction in disease ...